Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Indivior UK Limited, The Chapleo Building, Henry Boot Way, Priory Park, Hull, HU4 7DY, United Kingdom
Temgesic Injection 1ml.
| Pharmaceutical Form |
|---|
|
Solution for injection. |
Each ml contains buprenorphine hydrochloride 324 µg, equivalent to 300 µg buprenorphine base.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Buprenorphine |
Buprenorphine is an opioid partial agonist/antagonist which attaches itself to the μ (mu) and κ (kappa) receptors of the brain. Its activity in opioid maintenance treatment is attributed to its slowly reversible link with the μ receptors which, over a prolonged period, minimises the need of illicit opioids for patients with opioid dependence. |
| List of Excipients |
|---|
|
Glucose monohydrate |
Sealed Type 1 glass ampoules.
Pack size: five ampoules containing 1 ml.
Indivior UK Limited, The Chapleo Building, Henry Boot Way, Priory Park, Hull, HU4 7DY, United Kingdom
PL 36699/0006
03/10/1977 / 17/05/2002
| Drug | Countries | |
|---|---|---|
| TEMGESIC | Austria, Germany, Finland, France, Hong Kong, Ireland, Mexico, Netherlands, New Zealand, Singapore, Tunisia, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
